What Is It?
Tirzepatide is a dual agonist of two gut-hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By activating both, it may enhance satiety, slow gastric emptying, and support insulin release in a manner some providers find complementary to GLP-1-only therapies. Under medical supervision, tirzepatide may support gradual weight loss and improved glycemic control as part of a broader treatment plan that includes nutrition and activity guidance.
What May It Support?
- Appetite regulation
- Medical weight management
- Blood sugar control
- Metabolic health
Which Programs May Include It?
Where It Fits
Simultaneously activates GLP-1 and GIP receptors in the pancreas, brain, and gut, which may increase satiety, reduce appetite, slow gastric emptying, and support insulin secretion.
Do I Need Bloodwork?
Follow-up visits every 4-12 weeks depending on treatment phase, with lab review at the interval determined by the provider.
Likely baseline panel may include: CBC, CMP, A1c, Lipid panel, TSH, Lipase, Pregnancy test when applicable
Important Safety Information
Common side effects may include:
- Nausea
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- Reduced appetite
- Fatigue during dose escalation
- Injection-site reactions
Gallbladder disease (including gallstones) has been reported
Kidney injury reported in patients with severe nausea, vomiting, or dehydration
Boxed warning for thyroid C-cell tumors observed in rodent studies; contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2
Hypoglycemia when combined with insulin or sulfonylureas
Reduced effectiveness of oral hormonal contraceptives during dose escalation
Drug interactions: May affect absorption of oral medications due to delayed gastric emptying. May reduce effectiveness of oral hormonal contraceptives during dose escalation; a barrier method or non-oral contraceptive may be discussed by your provider. Increases risk of hypoglycemia with insulin, sulfonylureas, or meglitinides.
Contraindications:
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Known hypersensitivity to tirzepatide or any product component
- Active severe gastrointestinal disease (case-by-case)
Regulatory Status
Tirzepatide is FDA-approved under specific brand-name products for chronic weight management (Zepbound) in eligible adults and for type 2 diabetes (Mounjaro). Product availability, formulation, and eligibility are determined by the provider based on medical history and current supply. Compounded tirzepatide formulations, when prescribed, are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Frequently Asked Questions
How is tirzepatide taken?
How is it different from semaglutide?
Do I need bloodwork before starting?
Is this medication right for me?
Consultation
Treatment is not automatically provided. A licensed medical provider must review your history, symptoms, medications, laboratory results, and treatment goals before determining eligibility.